Last reviewed · How we verify
GW685698
GW685698 is a selective antagonist of the P2X7 receptor, an ATP-gated ion channel involved in inflammatory and immune responses.
GW685698 is a selective antagonist of the P2X7 receptor, an ATP-gated ion channel involved in inflammatory and immune responses. Used for Rheumatoid arthritis, Inflammatory bowel disease.
At a glance
| Generic name | GW685698 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | P2X7 receptor antagonist |
| Target | P2X7 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
P2X7 receptor antagonism reduces the release of pro-inflammatory cytokines such as IL-1β and TNF-α by blocking ATP-mediated activation of immune cells. This mechanism is intended to suppress excessive inflammatory responses in conditions characterized by P2X7-driven pathology, particularly in inflammatory and autoimmune diseases.
Approved indications
- Rheumatoid arthritis
- Inflammatory bowel disease
Common side effects
- Headache
- Nausea
- Diarrhea
Key clinical trials
- A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma (PHASE3)
- Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma (PHASE3)
- Arnuity® Ellipta® Drug Use Investigation
- Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma (PHASE2)
- INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design (PHASE4)
- Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease (PHASE2)
- An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma (PHASE3)
- A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW685698 CI brief — competitive landscape report
- GW685698 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI